微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 0.09% | -91.82% | -65.38% | 117/159 | 4.1% | 迪哲医药 | 115.44% | 行业排名> |
| 2026-06-30 | 0.26% | -59.38% | -33.33% | 110/159 | 1.36% | 泽璟制药 | 44.02% | 行业排名> |
| 2026-03-31 | 0.39% | -23.53% | -67.5% | 110/159 | 0.06% | 泽璟制药 | 45.29% | 行业排名> |
| 2025-12-31 | 1.2% | -41.46% | 9.09% | 95/159 | -4.32% | 兴齐眼药 | 38.62% | 行业排名> |
| 2025-09-30 | 1.1% | 6.8% | 71.88% | 100/159 | 1.69% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | 0.64% | 128.57% | 25.49% | 99/159 | 0.34% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | 0.51% | 27.5% | -75.12% | 99/159 | -0.34% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | 2.05% | 64% | 99.03% | 89/159 | -9.4% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | 1.03% | 56.06% | 267.86% | 104/159 | 4.26% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 0.28% | -15.15% | -30% | 110/159 | 2.68% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 0.4% | 33.33% | -68% | 106/159 | 2.33% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 1.25% | 43.68% | 89.39% | 98/159 | -0.94% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 0.66% | 22.22% | 100% | 111/159 | 2.36% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 0.33% | 106.25% | 10% | 113/159 | 1.49% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 0.3% | 20% | -65.52% | 112/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 0.87% | -2.25% | 61.11% | 105/159 | 0.84% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 0.54% | -21.74% | 237.5% | 112/159 | 2.87% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 0.16% | -77.14% | -36% | 114/159 | 2.21% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 0.25% | 38.89% | -71.91% | 109/159 | 1.59% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 0.89% | 105.18% | 28.99% | 111/159 | 0.87% | ST人福 | 6.82% | 行业排名> |
| 2021-09-30 | 0.69% | 111.11% | -1.43% | 112/159 | 4.45% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 0.7% | 119.02% | 288.89% | 112/159 | 2.99% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 0.18% | 110.59% | 101.05% | 107/159 | 2.48% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | -17.19% | 70.87% | -176.81% | 126/159 | 3.82% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | -6.21% | -288.18% | -68.75% | 108/159 | 3.15% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | -3.68% | -279.51% | -116.47% | 117/159 | 4.28% | 中哲精化 | 45.32% | 行业排名> |
| 2020-03-31 | -1.7% | -258.88% | 97.12% | 101/159 | 2.23% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | -59.02% | -1411.56% | -1888.49% | 130/159 | 2.62% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 3.3% | 334.21% | 60.98% | 84/159 | 7.58% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 2.05% | -27.3% | 91.59% | 85/159 | 5.02% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 1.07% | -18.32% | -76.22% | 84/159 | 2.44% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 4.5% | -22.01% | 492.11% | 91/159 | 7.16% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 0.76% | -81.42% | -73.05% | 96/159 | 7.2% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 2.82% | -1.4% | 115.27% | 70/159 | 4.62% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 1.31% | -7.75% | -77.3% | 73/159 | 2.57% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 5.77% | 7.85% | 41.08% | 79/159 | 9.61% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 4.09% | 9.95% | 43.01% | 67/159 | 8.3% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 2.86% | 5.93% | 101.41% | 73/159 | 5.55% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 1.42% | -21.11% | -73.46% | 54/159 | 2.11% | 中哲精化 | 54.24% | 行业排名> |
| 2016-12-31 | 5.35% | 749.21% | 43.82% | 79/159 | 6.11% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 3.72% | 396% | 37.78% | 61/159 | 5.7% | ST南新 | 81.7% | 行业排名> |
| 2016-06-30 | 2.7% | 297.06% | 50% | 60/159 | 3.56% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 1.8% | 26.76% | 185.71% | 46/159 | 2.69% | 贝达药业 | 16.78% | 行业排名> |